Abbott said it has received all regulatory clearances necessary to buy the cancer screening firm.

The deal brings Exact Sciences' flagship screening test for colorectal cancer, Cologuard, under Abbott's umbrella.

Abbott (NYSE: ABT) announced today that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026.

Abbott closes $21B acquisition of Exact Sciences (EXAS) at $105/share. EXAS delisted from Nasdaq on March 23, 2026, becoming ...

Abbott (NYSE:ABT) announced today that it completed its acquisition of cancer diagnostics developer Exact Sciences.

Abbott Laboratories (NYSE:ABT) is one of the Best Conservative Stocks to Buy Right Now. On March 23, the company announced that it had completed the acquisition of Exact Sciences. As a result of this, ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% ...

MADISON, Wis. -- Abbott expects to close its acquisition of Exact Sciences on Monday, the healthcare giant said.

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. U.S. equity markets experienced a ...

MADISON, Wis., September 10, 2025 — Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...

View Exact Sciences Corporation EXAS stock quote prices, financial information, real-time forecasts, and company news from CNN.